BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Week in Review: Eddingpharm (Cayman) Inc. In-Licenses China Rights to Bone Drug for $2.7 Million Upfront


10/21/2013 8:47:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

October 19, 2013 --Eddingpharm in-licensed greater-China rights to a novel osteoporosis treatment from Ablynx, a Belgium biopharma, paying $2.7 million upfront, plus milestones and royalties; Dance Biopharm, a US biotech, will form a joint venture with Harmony Asset of Hong Kong to jointly develop Dance’s second-generation inhaled insulin; Miraculins, a Canadian maker of non-invasive diagnostic tests, signed a LOI to sell China rights for a diabetes test to China’s Cachet Pharma; WuXi PharmaTech reported that its Shanghai genomics clinical laboratory was certified by US Medicare/Medicaid Services, allowing WuXi to perform gene sequencing projects as part of a clinical trial; Mark Reilly, the former head of GlaxoSmithKline in China, is back in China cooperating with authorities, who have asked him not to leave the country; and CardioKinetix, a California medical device company, said two patients in China received the company’s catheter-based treatment for heart failure. More details….

Stock Symbols: (BR: ABLX) (TSX-V: MOM) (SHE: 002462) (NYSE: WX) (NYSE: GSK)

Help employers find you! Check out all the jobs and post your resume.


Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES